drugset / Trial / NCT04662151

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

NCT04662151 ↗

Phase 1 Completed 37 enrolled Airway Therapeutics, Inc.
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to babies born premature who receive an air-sham alone.

Timeline

Start
2021-09-01
Primary completion
2023-08-14
Completion
2024-05-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Zelpultide alfa Protein / enzyme biologic 2 mg/kg Other
Subject Zelpultide alfa Protein / enzyme biologic 4 mg/kg Other
Subject Zelpultide alfa Protein / enzyme biologic 6 mg/kg Other